Netupitant - palonosetron (Akynzo®) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
The National Health Care Institute has assessed the medicine netupitant/palonosetron (Akynzeo®), whereby they came to the following conclusion.
Based on the criteria of the Medicines Reimbursement System (GVS), netupitant/palonosetron is not interchangeable with any other product that is included in the GVS. Therefore it can be included in the GVS on List 1B for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, including highly emetogenic anthracycline and cyclophosphamide (A/C)-based chemotherapy. In cases of moderately emetogenic cancer chemotherapy there is no place for netupitant/palonosetron.